Figure 1

Renal tumor development blocked by administration of RAD001 with or without NVP-BEZ235 in the ENU-treated Tsc2^+- model. A-C. Dot plot analysis of gross kidney tumor score (A), microscopic kidney tumor score (B), and percent cellularity of each lesion (C) in ENU-treated Tsc2^+- mice at age 24 weeks that received either 1) placebo, 2) RAD001 10 mg/kg PO 5 d/week, 3) NVP-BEZ235 15 mg/kg PO QD, or 4) a combination of RAD001 and NVP-BEZ235 at the same dosage; all for four weeks from age 20 – 24 weeks. A, B: Each dot represents a mouse kidney. C: Each dot represents a mouse kidney cystadenoma. A, p < .001; B, p = .03; C, p NS; by Kruskal-Wallis test. D. Dot plot analysis of percent Ki-67+ cells in kidney tumors of mice with genotype and treatment as in A-C, but that were analyzed 3 or 5 days after initiation of treatment with RAD001 10 mg/kg PO QD at age 24 weeks. Each dot represents a mouse kidney cystadenoma. p < .0001 Kruskal-Wallis test.